Nigel Keith Davis

Pronec Ltd. engages in the research and experimental development on biotechnology. The company was founded on September 14, 2015 and is headquartered in Wirral, the United Kingdom.

Cambridge Theranostics (CTL) was founded in 2002 as a spin-out from Cambridge University, following the discovery of ALOA (Atherogenic Lipid-Oxidising Antibodies) by its founder Dr. Petyaev. It is privately funded. The Company continues to have a very strong research focus and now owns 10 granted patents in Europe, U.S.A, Eurasia and Japan the US, with a further 18 applications pending. They also conduct clinical studies with their partners in Europe, U.S. and Russia. CTL develops specially formulated supplements to provide the correct doses of nutrients in a form that is effective. Its scientists investigate the mechanisms by which nutrients prevent disease and develop highly effective formulations. Together with their clinical partners, they confirm that the nutrient reaches the correct part of the body and is active.